News

Affordable Care Act Marketplace deductibles hit a record 37% increase in 2026 as expired enhanced tax credits pushed millions of enrollees toward cheaper, higher-deductible bronze plans.

Findings may help with the selection problem of which ALK inhibitor to use, as the number of treatments in that category for non-small cell lung cancer has increased.

Researchers found that the cost of recommended sunscreen use can range from approximately $40 to more than $1,400 per year, depending on sunscreen prices and clothing choices.

GLP-1 medications, especially for diabetes, will remain an influential cost driver in drug spending this year, supported by broader prescriber adoption and patient demand.

Immgolis and Immgolis Intri have the same indications as Simponi and Simponi Aria, treating patients with rheumatoid arthritis and ulcerative colitis. The biosimilars will be available in the fourth quarter of this year.

Navitus clients saw prescription drug costs rise 8.4% in 2025, driven by specialty medications, GLP-1s, oncology and dermatology spending.

Self-insured employers and other payers are the startup's customers, but Aradigm CEO and co-founder Will Shrank says the company is looking to bridge the gaps among all stakeholders in burgeoning cell and gene therapy category.

Shrank, a longtime member of the MHE editorial advisory board, discusses the mainstreaming of CAR-T therapy and still-unique aspects of gene therapy

The FDA approved two new cancer drugs this week, one for rare non-Hodgkin lymphoma and another for elderly acute myeloid leukemia patients.

21 million U.S. adults reported pain disrupting daily life despite having no formal pain-related diagnosis, finds an analysis done by researchers at The University of Texas at Arlington.

Young adults with HIV who experience financial instability are significantly more likely to struggle with adhering to antiretroviral therapy, highlighting how economic hardship can directly impact treatment success.

UnitedHealthcare prior authorization changes cut approvals 30% as AHIP pushes e‑processing; Larry Levitt of KFF warns voluntary moves may not last.

In mouse models, semaglutide benefited the liver even in the absence of weight loss. The benefit appears to come via a particular type of liver cell.

A French study found that a higher dose of ivermectin was not more effective than the standard dose when combined with topical therapy for treating severe scabies.

Prior authorization reform, AI deployment, GLP-1 management and specialty drug costs are among the issues reshaping payer and provider strategy this year.

Kyle Diamantas, the FDA deputy commissioner for food, has been named interim FDA commissioner after Makary's resignation today.

Researchers join the hunt for a test that could detect pancreatic cancer at a much earlier, more treatable stage.

The company says it made an upfront payment of $25 million for a global license to develop and commercialize the ARO-PHPLA3.

Optum Rx will shift to flat, per-member fees by 2027, eliminating spread pricing and passing 100% of drug rebates directly to clients.

Researchers at the University of Texas Health Science Center at Houston have created an organs-on-a-chip system that could provide a way to study pancreatic cancer biology and predict how therapies may perform in patients.

Survey reveals payers lag on CMS priorization authorization rule; learn how to operationalize APIs, fix workflows, and unlock interoperability value.

A phase 1b trial found that injecting ipilimumab directly into melanoma tumors alongside intravenous nivolumab reduced severe treatment-related adverse events while maintaining encouraging antitumor activity.

Will Shrank, M.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is leading a startup company focused on managing the cost and delivery fo cell and gene therapy.

Hospital prices have risen faster than other healthcare prices, and some say consolidation into large health systems is to blame. Hospitals counter that they are price takers, not setters.

More people stop taking the glucagon-like peptide 1 (GLP-1) drugs for weight loss than is commonly recognized. Insurance coverage is patchy, but for those who do have it, some pharmacy benefit managers have launched programs designed to help keep people keep taking their GLP-1.

A pilot study of demodex mites and antimicrobial peptides published in the Journal of the American Academy of Dermatology found biologic differences between sensitive skin syndrome and rosacea, suggesting the conditions are distinct despite sharing similar symptoms and triggers.

The Wall Street Journal is reporting that President Donald Trump has signed off on Makary's dismissal.

A survey from the Business Group on Health finds that employers covering GLP-1 weight loss drugs are reconsidering that coverage in 2027 due to high costs.